maria luz calibo
Oct 21, 2011

Tekmira Provides Periodic Update to Litigation - MarketWatch

Tekmira Pharmaceuticals Corporation TKMR +2.94% CA:TKM +3.43% , a leading developer of RNA interference (RNAi) therapeutics, today provided a periodic update on its ongoing litigation against Alnylam Pharmaceuticals, Inc. ("Alnylam") and AlCana Technologies, Inc. ("AlCana"), as well as an update to its financial guidance.